Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis.

Autor:	Minich A; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Arisar FAQ; Ajmera Transplant Centre, Toronto General Hospital, University Health Network, Toronto, Canada.; Division of Gastroenterology and Hepatology, Department of Medicine, University of Toronto, Canada.; National Institute of Liver & GI Diseases, Dow University of Health Sciences, Karachi, Pakistan., Shaikh NS; Ajmera Transplant Centre, Toronto General Hospital, University Health Network, Toronto, Canada., Herman L; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Azhie A; Ajmera Transplant Centre, Toronto General Hospital, University Health Network, Toronto, Canada., Orchanian-Cheff A; Library and Information Services, University Health Network, Toronto, Ontario, Canada., Patel K; Division of Gastroenterology and Hepatology, Department of Medicine, University of Toronto, Canada.; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Canada., Keshavarzi S; Department of Biostatistics, Princess Margaret Cancer Center, University Health Network, Toronto, Canada.; Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada., Bhat M; Ajmera Transplant Centre, Toronto General Hospital, University Health Network, Toronto, Canada.; Division of Gastroenterology and Hepatology, Department of Medicine, University of Toronto, Canada.
Jazyk:	angličtina
Zdroj:	EClinicalMedicine [EClinicalMedicine] 2022 Jul 01; Vol. 50, pp. 101534. Date of Electronic Publication: 2022 Jul 01 (Print Publication: 2022).
DOI:	10.1016/j.eclinm.2022.101534
Abstrakt:	Background: Non-alcoholic steatohepatitis (NASH) is the second-leading indication for liver transplantation (LT) worldwide and is projected to become the leading indication. Our study aimed to determine clinical variables that predict post-LT survival in NASH. Methods: A systematic review and meta-analysis was performed. On June 18, 2020 and April 28, 2022, Ovid MEDLINE ALL, Ovid Embase, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials were searched. No date limits were applied. Inclusion criteria specified the type of study and our study's population/comparison and outcome/timepoints. Pediatric, animal, retransplantation-only, and studies classifying cryptogenic cirrhosis patients with body mass index (BMI) <30 as NASH were excluded. Studies with duplicate cohorts and missing information were excluded from the meta-analysis. Studies were appraised using the Newcastle-Ottawa Scale. This study was preregistered in PROSPERO (CRD42020196915). Findings: Out of 8583 studies identified, 25 studies were included in the systematic review, while 5 studies were included in the meta-analysis. Our quantitative review suggested that the following variables were predictive of post-LT NASH patient survival: recipient age, functional status, pre-LT hepatoma, model for end-stage liver disease (MELD) score, diabetes mellitus (DM), pre-LT dialysis, hepatic encephalopathy, portal vein thrombosis, hospitalization/ICU at LT, and year of LT. Predictors of graft survival included recipient age, BMI, pre-LT dialysis, and DM. Our pooled meta-analyses included five predictors of patient survival. Increased patient mortality was associated with older recipient age (HR=2·07, 95%CI: 1·71-2·50, I 2 =0, τ 2 =0, p =0·40) and pretransplant DM (HR=1·18, 95%CI: 1·08-1·28, I 2 =0, τ 2 =0, p =0·76). Interpretation: Our systematic review and meta-analysis aimed to synthesise predictive variables of mortality in LT NASH patients. Clinically, this might help to identify modifiable risk factors that can be optimized in the post-transplant setting to improve patient outcomes and optimises decision making in the resource-limited LT setting. Funding: Toronto General and Western Hospital Foundation. Competing Interests: Dr. Bhat reports grants from Novo Nordisk, grants from Ipsen, grants from Paladin, grants from Natera, grants from Oncoustics, grants from MedoAI, grants from Lallemand, personal fees from Novartis, personal fees from Lupin, outside the submitted work. All other authors have nothing to disclose. (© 2022 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu